Table 3

Prevalence of CD44+/CD24−/low tumor cells and treatment response

Recurrence
EFS
OVS
TreatmentnNo, n (%)Yes, n (%)PLog rankPLog rankP
CMF502129
    ≤10%15 (71.4)24 (82.8)0.490.620.430.510.48
    >10%6 (28.6)5 (17.2)
Anthracycline431231
    ≤10%9 (75.0)25 (80.6)0.690.310.58890.35
    >10%3 (25.0)6 (19.4)
Tamoxifen431726
    ≤10%14 (82.4)18 (69.2)0.480.090.271.210.76
    >10%3 (17.6)8 (30.8)
Radiotherapy702149
    ≤10%18 (85.7)39 (79.6)0.740.910.340.470.49
    >10%3 (14.3)10 (20.4)
  • NOTE. Treatment groups are selected on a “Yes” or “No” basis with some patients having received multiple treatment.

    Abbreviations: EFS, event-free survival; OVS, overall survival; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil.